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Abstract 
Molecular networks in neurological diseases are complex. Despite this fact, contemporary biomarkers 
are in most cases interpreted in isolation, leading to a significant loss of information and power. We 
present an analytical approach to scrutinize and combine information from biomarkers originating from 
multiple sources with the aim of discovering a condensed set of biomarkers that in combination could 
distinguish the progressive degenerative phenotype of multiple sclerosis (SPMS) from the 
relapsing-remitting phenotype (RRMS). 
Methods: Clinical and magnetic resonance imaging (MRI) data were integrated with data from protein 
and metabolite measurements of cerebrospinal fluid, and a method was developed to sift through all the 
variables to establish a small set of highly informative measurements. This prospective study included 16 
SPMS patients, 30 RRMS patients and 10 controls. Protein concentrations were quantitated with 
multiplexed fluorescent bead-based immunoassays and ELISA. The metabolome was recorded using 
liquid chromatography-mass spectrometry. Clinical follow-up data of the SPMS patients were used to 
assess disease progression and development of disability. 
Results: Eleven variables were in combination able to distinguish SPMS from RRMS patients with high 
confidence superior to any single measurement. The identified variables consisted of three MRI variables: 
the size of the spinal cord and the third ventricle and the total number of T1 hypointense lesions; six 
proteins: galectin-9, monocyte chemoattractant protein-1 (MCP-1), transforming growth factor alpha 
(TGF-α), tumor necrosis factor alpha (TNF-α), soluble CD40L (sCD40L) and platelet-derived growth 
factor AA (PDGF-AA); and two metabolites: 20β-dihydrocortisol (20β-DHF) and indolepyruvate. 
The proteins myelin basic protein (MBP) and macrophage-derived chemokine (MDC), as well as the 
metabolites 20β-DHF and 5,6-dihydroxyprostaglandin F1a (5,6-DH-PGF1), were identified as potential 
biomarkers of disability progression. 
Conclusion: Our study demonstrates, in a limited but well-defined and data-rich cohort, the importance 
and value of combining multiple biomarkers to aid diagnostics and track disease progression. 
Key words: data integration, multiple sclerosis, disease progression, metabolomics, biomarker 
 
Ivyspring  
International Publisher 
 Theranostics 2018, Vol. 8, Issue 16 
 
 
http://www.thno.org 
4478 
Introduction 
Traditionally, a biomarker is viewed as a 
characteristic that is objectively measured (e.g., a 
biological substance) and may affect interpretation or 
prediction of the incidence or outcome of disease [1,2]. 
In contrast, the molecular events in e.g., neurological 
diseases, are often complex, emphasizing that no 
single marker or source of information alone can 
reflect the full pathology. Recent advances in modern 
technologies have enabled comprehensive 
measurements at molecular and cellular levels, 
utilizing different biological specimens, tissues and 
radiological assessments. Considering the complexity 
of pathological events, integrating information from 
multiple sources can therefore result in a more refined 
tool for diagnostic and prognostic purposes. This 
concept is known as multianalyte assays with 
algorithmic analyses (MAAAs). Yet, the use of 
algorithm-based analyses in the clinic is very limited. 
A recent successful example of an MAAA is the 
improved test for prostate cancer [3]. 
Multiple sclerosis (MS) is an immune-mediated 
neurological disease that exists in two distinct 
phenotypes. At onset, the most common is 
relapsing-remitting MS (RRMS) in which focal 
inflammation in the central nervous system (CNS) 
appears over time, giving rise to clinical relapses, 
followed by a complete or partial recovery. 
Eventually, most RRMS patients will develop a 
progressively degenerative phenotype (secondary 
progressive MS, SPMS) with neurodegeneration, 
brain atrophy and accumulation of disability. The 
onset of SPMS is detected by continuous disability 
accumulation, monitored through the expanded 
disability status scale (EDSS) score and the presence 
of steady neurodegeneration in the CNS, monitored 
with magnetic resonance imaging (MRI). 
Consequently, the diagnosis of SPMS will be made 
retrospectively, potentially years after the shift has 
occurred. Once a patient has transitioned, there are 
currently no sufficient methods to treat or predict the 
disease progression [4]. 
In MS, the measurements of a broad range of 
proteins (proteomics) and low-weight intermediates 
(metabolomics) have, in combination with advanced 
multivariate methods, shown great promise in 
distinguishing MS and controls and to some extent 
the different subtypes of MS [5–10]. However, the 
high-dimensional nature of omics measurements 
makes them often impractical to implement in clinical 
practice.  
To overcome this limitation, we developed an 
integrative analysis approach to acquire a small set of 
highly informative variables that can be used in 
combination to identify patients developing SPMS. 
Utilizing clinical, radiological and protein and 
metabolite measurements in cerebrospinal fluid 
(CSF), we also aimed at identifying a number of 
variables that associate with a worse prognosis for 
SPMS patients. These variables may prove to be of 
value for monitoring future therapeutic interventions 
in treatment of SPMS patients.  
Methods 
Ethics approval 
All participants provided written informed 
consent, and the study was approved by the Regional 
Ethical Board of Uppsala (DNr 2008/182). 
Subjects 
The study cohort consisted of 56 subjects: 30 
were diagnosed with RRMS, 16 with SPMS, and 10 
were controls with other, non-inflammatory, 
neurological diseases (e.g., idiopathic intracranial 
hypertension or thunderclap headache). All MS 
patients met the revised McDonald’s criteria for MS 
diagnosis [11]. Seventeen of the RRMS and two of the 
SPMS patients were inflammatory active with 
presence of gadolinium (Gd)-enhancing lesions on 
MRI. One of the SPMS patients was on a 
disease-modifying drug (DMD) treatment, while 15 
RRMS patients were on a DMD. The demographics of 
the cohort are summarized in Table 1 and DMD 
details in Table S3. 
 
Table 1. Clinical and demographic data including 
follow-up data of the patients. Four of the RRMS patients had 
transitioned to SPMS, one of whom was deceased. 
Cohort Controls RRMS SPMS 
n 10 30 16 
On treatment, n 0 15 1 
Age, mean(±SD) 39(±13.1) 39(±10.6) 58(±9.3) 
Female/Male 6/4 21/9 10/6 
EDSS, median(range) n/a 2.0(0–7.5) 5.5(3.0–7.5) 
Disease duration in 
months, mean(±SD) 
n/a 115(±103.8) 281(±128.3) 
Follow-up  RRMS SPMS 
n  27 13 
ΔEDSS, median(range)  0.0(-3.5–3.0) 1.5(0–4.0) 
Time interval in 
months, mean(±SD) 
 68(±15.4) 
 
55(±18.6) 
Transitioned, n  4 n/a 
Deceased, n  1 0 
EDSS: expanded disability status scale; n/a: not applicable; RRMS: 
relapsing-remitting multiple sclerosis; SD: standard deviation; SPMS: secondary 
progressive multiple sclerosis. 
 
All participants underwent a clinical 
examination with EDSS grading and lumbar puncture 
at inclusion. MRI was performed within a week of the 
lumbar puncture at 1.5 T using the same imager and 
imaging protocol in all examinations. Gadopentetate 
dimeglumine (Magnevist®, 0.4 mL/kg body weight, 
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i.e., double dose) was used as a contrast agent, and 
MR images were analyzed visually. More details on 
how the T2 score, number of T1 and large T1 lesions 
were extracted can be found in the supplementary 
information, whereas other MRI-extracted measures 
have been previously published by us [12]. 
Follow-up 
Baseline data were acquired for the 46 patients 
and 10 controls. Follow-up data were available for 40 
patients. The mean follow-up time was 5±1.4 years. At 
the end of the follow-up, four patients had 
transitioned from RRMS to SPMS. One of these was 
deceased. These four patients were excluded from 
subsequent analyses and were used instead to 
evaluate the ability to predict SPMS at an early stage. 
The patients lacking follow-up data were assumed to 
have the diagnosis they were given at inclusion. 
Sample collection 
The lumbar puncture was performed through 
the L3/L4 or L4/L5 interspace, and CSF was collected 
in a polypropylene tube that was centrifuged for 5 
min at 250 ×g at room temperature. The supernatant 
was transferred, gently mixed and aliquoted in 
polypropylene tubes stored at -80 °C until analysis. 
Protein quantification 
CD27 was measured by sandwich ELISA kit, 
(DY382, R&D Systems, Minneapolis, MN, USA). The 
assay was calibrated against recombinant human 
CD27 and had a total coefficient of variation of 
approximately 5%. 
CSF concentrations of amyloid β peptides 
ending at amino acids 38, 40 and 42 (Aβ38, Aβ40 and 
Aβ42, respectively) were measured using the Meso 
Scale Discovery Abeta Triplex assay (MSD, Rockville, 
MD). CSF T-tau and P-tau concentrations were 
measured using INNOTEST ELISAs (Fujirebio, 
Ghent, Belgium). CSF monocyte chemoattractant 
protein 1 (MCP-1) concentration was measured using 
the V-PLEX Human MCP-1 Kit (MSD, Rockville, MD). 
Intra-assay coefficients of variation were below 10% 
for all analyses. 
Albumin concentrations in plasma and CSF were 
measured immunochemically in a Cobas 501 analyzer 
(Roche Diagnostics, Rotkreuz, Switzerland) with 
reagents from the same manufacturer. Experienced 
and board-certified laboratory technicians, blinded to 
clinical data, performed all analyses in one round of 
experiments using one batch of reagents per assay. 
The remaining 39 out of the 52 clinical, 
radiological and protein (CRP) measurements had 
been previously characterized and published by us, 
including age and gender [12–15]. The mean and 
standard deviation of all CRP measurements in each 
diagnostic group are summarized in Table S4. 
Metabolite extraction 
CSF samples were thawed on ice, and 100 µL 
was transferred and mixed with 410 µL ice-cold 
methanol (MeOH) supplemented with an internal 
standard cocktail (D4-6keto-prostaglandin-F1-alpha, 
D4-thromboxane-B2, D4-prostaglandin-F2-alpha, D4- 
prostaglandin-E2, D4-prostaglandin-D2, D4-15- 
deoxy-delta12, 14-prostaglandin-J2, D4-cortisol and 
levonorgestrel) at a final concentration of 0.25 µM. 
The samples were further vortexed for 15 s and 
incubated at -20 °C for 30 min, followed by 
centrifugation at 20400 ×g for 12 min at 4 °C. The 
supernatants were transferred to fresh Eppendorf 
tubes and dried using a centrifugal vacuum 
concentrator (overnight). 
Upon analysis, the dried samples were 
reconstituted in 100 µL of 5% MeOH, 0.1% formic acid 
(FA) and 94.9% deionized MilliQ water. 10 µL of each 
sample was pooled to create a quality control (QC) 
sample to be injected repeatedly to monitor the 
performance throughout the analysis. 
Mass spectrometry analysis 
The samples were injected in a constrained 
randomized order, where they were divided into 
groups of eight that were injected twice for technical 
duplicates (the second injections were done in 
reversed order to prohibit patterns in potential 
carryover effects). A QC injection was done every 16th 
sample and a blank injection every 8th. Finally, a 2-fold 
serial dilution series ranging from 0.5 to 32 µL QC was 
injected. 
The mass spectrometry analyses were performed 
using a Thermo Ultimate 3000 HPLC and Thermo 
Q-Exactive Orbitrap mass spectrometer. 10 µL sample 
was injected to a Thermo Accucore aQ RP C18 column 
(100 × 2.1 mm, 2.6 µm particle size). The analytical 
gradient was initiated with an isocratic flow for 3 min 
(0% B), followed by a 2.6 min gradient (0–10% B), 8.3 
min (10–100% B) and 3 min (100% B), followed, 
finally, by re-equilibration and washing of the column 
for 3 min (0% B), where A is 0.1% FA in MilliQ water 
and B is 89.9% acetonitrile, 10% isopropanol and 0.1% 
FA. Mass spectrometry data were acquired in profile 
mode (in positive and negative ionization mode), 
using a mass range of 70–900 m/z during the first 5 
min and 148–900 m/z in the following 15 min (to 
avoid low mass contaminants) in the positive 
ionization mode and 70–900 m/z throughout in 
negative ionization mode. To improve the 
identification of metabolites, eight tandem mass 
spectrometry analyses in positive and negative 
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ionization mode were performed separately on 
pooled samples (RRMS, SPMS, control and global 
pools). 
Quantification 
The acquired raw data was converted to an open 
source format (.mzML). Peaks were picked using 
msconvert from ProteoWizard [16] and preprocessed 
using the following pipeline within the OpenMS 
platform [17]. The peak-picked data were quantified 
by FeatureFinderMetabo [18], and the resulting features 
were linked across the samples using 
FeatureLinkerUnlabelledQT [19], allowing 10 s 
retention-time tolerance and 5 ppm mass deviation 
(this was performed irrespective of charge state across 
the samples). The non-default parameters can be 
found in Table S5. 
Metabolite identification 
Two strategies were used for metabolite 
identification: 1) the experimentally measured peaks 
were compared to in silico fragmented spectra of the 
metabolites in the Human Metabolome Database 
(HMDB) [20], employing the Phenomenal 
infrastructure [21] and 2) the experimental MS2 
spectra were manually curated and matched in 
mzcloud [22]. While mzcloud, in contrast to the de novo 
approach, has the advantage of matching against 
actual measured data on libraries of metabolites, it 
obviously lacks many metabolites that have not yet 
been measured and characterized, a weakness that is 
met by the de novo approach, where theoretical MS2 
spectra for all metabolites in HMDB are present. 
In cases when different identities were suggested 
by the two different approaches, the identity 
suggested by the de novo approach was chosen 
(implying that the identity was not present in mzcloud 
or that there was no clear match in mzcloud). 
Statistical analysis 
The quantified data was loaded into the 
statistical software environment R v3.4.0 [23] and 
features without established charge were removed. 
Blank filtering was performed according to our 
previously introduced pipeline [24]. A 
quality-filtering procedure was done using the 
dilution series requiring the spectral features in the 
series to have at least an absolute Pearson correlation 
of 0.5 with the injection volume. To stabilize 
variances, the intensity values were replaced by their 
log2 value, before potential sample outliers were 
investigated visually based on the total ion count of 
each sample. No sample outliers were found. 
To reduce the intensity decrease over run time, 
the spectral features were normalized by the internal 
standards. The in-between-replicate Pearson 
correlation was calculated (minimum replicate 
correlation achieved was 0.95) and the replicates were 
averaged. Spearman’s rank correlation coefficients 
were calculated between the albumin ratio and the 
spectral features to eliminate features that may 
originate from blood (leaking through the blood-brain 
barrier). Features that acquired a statistically 
significant (p-value<0.05) absolute correlation higher 
than 0.5 were removed. 
Finally, only metabolites with an established de 
novo identity were used in analysis with a coverage 
within metabolic features of at least 75%. Remaining 
missing values were replaced by the average feature 
value.  
The age dependence was evaluated per 
metabolite and protein, assuming a linear relation 
using Pearson’s correlation analysis, where a p<0.05 
was seen as a significant dependence. Age-dependent 
metabolites or proteins were age corrected by fitting a 
linear model (R function lm) to their levels in the 
controls and RRMS patients, with age as the 
explanatory variable. The age coefficient was 
extracted from the model and used to correct the 
metabolite or protein values in all individuals [25,26]. 
Multivariate modelling and variable selection 
The CRP data and metabolomics data were 
separately subjected to partial least square 
discriminant analysis (PLS-DA) to target the 
differences between classes using the R package ropls 
[27], with the number of components predefined as 
two. This was performed using the class labels RRMS, 
SPMS and controls, comparing all groups against each 
other (referred to as the Global model) and RRMS vs. 
SPMS. The most significant variables were obtained 
using a combined “Variable Importance in the 
Projection” (VIP) which is commonly used to assess 
the importance of the X-variables in multivariate 
models. 
To attain measures separating SPMS from RRMS 
that also differ from control levels, ten variables 
achieving the highest VIP values were extracted from 
each model, and the intersections between the Global 
and RRMS vs. SPMS variables were obtained. These 
variables (CRP and metabolic) were evaluated by 
PLS-DA separately, as reduced sets, and combined 
into a new dataset (CRPM), employing the same class 
labels as used previously (Global and RRMS vs. 
SPMS).  
To reduce the risk of overfitting, i.e., to extract 
variation unique to the dataset alone, the full 
procedure, including the variable selection, was 
performed and evaluated using a 5-fold 
cross-validation (CV) repeated ten times. Briefly, the 
5-fold CV divides the data into five balanced groups 
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using stratified sampling. Four of these groups are 
used for training the model, while the fifth is held out 
and used for validation and performance estimation. 
The procedure is repeated five times, so that each 
group may act as the validation cohort. Balanced error 
rates (BER), accounting for class sizes, were calculated 
for each model to estimate an overall predictive 
performance, and SPMS-specific error rates (ER) were 
obtained to establish the performance of SPMS 
detection. This analytical strategy is illustrated in 
Figure 1, and the complete code has been made 
publicly available on Github (https://github.com/ 
stephanieherman/variable-selection). Additionally, to 
evaluate any potential overfitting, PLS-DA was 
performed on the CRP and metabolomics dataset 
including all individuals, and R2 and Q2 values were 
extracted. 
The consensus variables (the ones with the 
highest average VIPs) were filtered for redundancies 
using Spearman’s ranked correlation analyses, 
excluding variables that were statistically significantly 
(p<0.05) correlated (r>0.80) as well as metabolites 
missing highly confident identities. Finally, to 
combine variable information, principal component 
analysis (PCA) was used (R function prcomp with 
centered and scaled variables) to compress the 
variables into two principal components. A Welch’s 
t-test was done between the RRMS and SPMS scores 
in the first principal component and for each separate 
variable alone. Similarly, the receiver operating 
characteristic (ROC) curves for each separate variable 
as well as the first principal component were 
computed with corresponding areas under the ROC 
curve (AUROC) using the R package pROC [28]. 
Disease progression 
To identify variables that associate with the 
disease progression of SPMS patients, the increases in 
EDSS scores at the end of the follow-up 
period were assessed by an experienced 
neurologist and categorized into three 
groups by clinical degree of change. 
Group 1 consisted of patients whose 
EDSS scores were stable with no change 
during the follow-up period. An 
intermediate group 2 increased in EDSS 
by 0.5–1.5 if the initial EDSS was <5.5 or 
by 0.5–1 if the initial EDSS was ≥5.5. 
Finally, group 3 consisted of patients 
who had deteriorated significantly in 
the follow-up period, whose EDSS 
increased by >1.5 if the initial EDSS was 
<5.5 or by >1 if the initial EDSS was 
≥5.5. This stratification aimed to take 
the clinical severity into account, which 
is not reflected by the EDSS scoring. 
The EDSS increase and corresponding 
group for each SPMS patient can be 
found in Table S6. To find variables 
that statistically significantly (p<0.05) 
varied between the groups, 
Kruskal-Wallis tests were done on the 
metabolites in the reduced 
metabolomics dataset as well as the 
CRP variables. 
Results 
The CRP data distinguished RRMS 
and SPMS with a 22% error rate 
To investigate the ability to 
distinguish all groups (Global), the CRP 
data were modelled using PLS-DA after 
age correcting three age-dependent 
 
 
Figure 1. Variable selection and evaluation procedure. The metabolomics and the CRP datasets were 
separately evaluated, and two models for each dataset, Global and RRMS vs. SPMS, were built using partial least 
squares discriminant analysis (PLS-DA). The top ten variables, contributing the most to each model, were 
compared, and the overlapping variables modelled using PLS-DA (the reduced models). Additionally, the 
reduced variable sets from the metabolomics and the CRP dataset were combined, creating the CRPM 
dataset, and two CRPM models were built, Global and RRMS vs. SPMS. The full procedure was evaluated using 
a 5-fold cross-validation (CV) repeated ten times, where four fifths of the data were used for modelling and 
variable selection and a fifth for validation. CRP: clinical, radiological and protein; CRPM: clinical, radiological, 
protein and metabolite; RRMS: relapsing-remitting multiple sclerosis; SPMS: secondary progressive multiple 
sclerosis. 
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proteins. A BER value for classifying all classes and an 
SPMS-specific ER were estimated (BER: 0.44±0.122, 
SPMS ER: 0.18±0.207), i.e., the SPMS was the only 
group that the model was able to moderately 
separate. To explore the variable contribution, VIP 
values were extracted, which indicated that EDSS 
contributed the most, followed by disease duration, 
age and the size of the spinal cord and third ventricle. 
EDSS, age and disease duration are essentially 
demonstrating that SPMS patients in general are 
older, have had the disease for a longer time and are 
more disabled than the other groups. These variables 
cannot be used for diagnostic purposes and were 
therefore excluded from further analyses. In addition, 
redundant variables giving the same type of 
information were also excluded from the CRP data 
(specifically large T1, T1 and T2 scores). 
When these variables were removed, the 
performance was decreased (BER: 0.48±0.111, SPMS 
ER: 0.28±0.271). Excluding the control group, 
comparing RRMS and SPMS patients (RRMS vs. 
SPMS) resulted in a BER of 0.22±0.103 (Table 2). A 
visualization of the CRP RRMS vs. SPMS model built 
on all patients is shown in Figure 2A, where patients 
transitioning from RRMS to SPMS (n=4) were 
projected into the model space, with one of them 
located in the SPMS space and one in-between. 
Reducing the CRP variables down to the overlapping 
top ten variables from the Global and the RRMS vs. 
SPMS models resulted in improved performances for 
the Global model (BER: 0.38±0.135, SPMS ER: 
0.23±0.249) and the RRMS vs. SPMS model (BER: 
0.20±0.138). 
 
Table 2. The overall and SPMS-specific cross-validated (CV) error rates (ER) achieved by the respective models. The 
overall CV error is a balanced error rate (BER), which is adjusted for class sizes so that 0.50 corresponds to random chance. Both the 
metabolomics and CRP models did not perform well for distinguishing between all groups (BER values close to 0.5). However, both 
models were moderately able to distinguish the SPMS patients from remaining groups. As for RRMS vs. SPMS, the CRP model obtained a 
BER value of 0.22 and the metabolomics model a BER value of 0.20. When reducing the variables to the overlapping top ten variables, the 
BER value was improved for the CRP model whereas it increased for the metabolomics model (0.20 and 0.30 respectively). Combining the 
top CRP and metabolic variables (CRPM) resulted in a BER value of 0.23, comparable to the value achieved by the full models. 
CV error, mean (±SD) CRP model 
n=46 
Metabolomics model 
n=606 
Reduced CRP model 
n=1–10 
Reduced metabolomics model 
n=1–10 
CRPM model 
n=2–20 
Global      
Overall (BER) 0.48(±0.111) 0.42(±0.119) 0.38(±0.135) 0.55(±0.120) 0.45(±0.145) 
SPMS (ER) 0.28(±0.271) 0.26(±0.248) 0.23(±0.249) 0.39(±0.302) 0.34(±0.230) 
RRMS vs. SPMS      
Overall (BER) 0.22(±0.103) 0.20(±0.142) 0.20(±0.138) 0.30(±0.167) 0.23(±0.149) 
BER: balancer error rate; CV: cross-validation; CRP: clinical, radiological and protein; CRPM: clinical, radiological, protein and metabolite; ER: error rate; RRMS: 
relapsing-remitting multiple sclerosis; SD: standard deviation; SPMS: secondary progressive multiple sclerosis. 
 
 
 
Figure 2. The CRP and metabolomics RRMS vs. SPMS models built using all measurements and patients. The four transitioning patients have been projected into 
the model space and marked with blue stars. (A) A visualization of the CRP model with quality metrics of R2=0.70: p<0.05 and Q2=0.35: p<0.05. (B) A visualization of the 
metabolomics model with quality metrics of R2=0.87: p<0.05 and Q2=0.64: p<0.05. RRMS: relapsing-remitting multiple sclerosis; SPMS: secondary progressive multiple sclerosis. 
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The metabolome distinguished RRMS and 
SPMS with a 20% error rate 
To attain the metabolomics signatures for further 
assessment, the CSF metabolomes of the study cohort 
were measured using liquid chromatography-mass 
spectrometry. After removal of contaminants and 
spectral features potentially originating from blood, a 
total of 606 metabolic features with a coverage of 75% 
(of which 21% correlated and were corrected for age) 
were used to build the metabolomics models. The 
Global metabolomics model (BER: 0.42±0.119, SPMS 
ER: 0.26±0.248) as well as the RRMS vs. SPMS model 
(BER of 0.20±0.142) attained higher performances than 
the CRP models, where the ERs again indicate that 
SPMS was the only group that the models were able to 
separate (Table 2). A visualization of the 
metabolomics RRMS vs. SPMS model built on all 
patients is shown in Figure 2B, where patients 
transitioning from RRMS to SPMS have been 
projected into the model space. Reducing the 
metabolites down to the overlapping top ten variables 
from the Global and the RRMS vs. SPMS models 
resulted in decreased performances for both models 
(Table 2). 
Integration of CRP and metabolite 
measurements 
To evaluate if a combination of CRP and 
metabolic variables can improve the prediction 
accuracy using only a limited number of variables, the 
overlapping top ten variables from the Global and 
RRMS vs. SPMS models of each dataset were 
combined into the CRPM dataset. Evaluated through 
CV over the full procedure (Figure 1), the CRPM 
Global model attained a comparable estimated 
performance (BER: 0.45±0.145, SPMS ER: 0.34±0.230), 
and the RRMS vs. SPMS model achieved a BER value 
of 0.23±0.149, which is comparable to that of the full 
models (Table 2). 
The consensus of the overlapping top ten CRP 
variables from the Global and RRMS vs. SPMS models 
were: the size of the spinal cord and third ventricle, 
galectin-9, total T1, MCP-1, transforming growth 
factor alpha (TGF-α), tumor necrosis factor alpha 
(TNF-α), soluble CD40L (sCD40L) and 
platelet-derived growth factor AA (PDGF-AA). For 
the metabolomics data, the consensus overlapping top 
ten metabolic features were identified as: 
5,6-dihydroxyprostaglandin F1a (5,6-DH-PGF1), 
20β-dihydrocortisol (20β-DHF), indolepyruvate, and 
four that remained unidentified after manual 
curation, referred to as X1, X2, X3 and X4 (Table S7). 
These were combined into the consensus CRPM 
dataset that was filtered for potential redundancies in 
information using Spearman’s ranked correlation 
analyses between all variables. Metabolic features 
with an uncertain identity and variables that achieved 
a statistically significant (p<0.05) correlation higher 
 
Figure 3. The Spearman’s ranked correlations between the consensus variables chosen in the variable selection. Non-significant correlations (p>0.05) have been 
left blank. 
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than 0.80 were excluded (Figure 3). For correlating 
metabolites, the metabolite with the highest 
identification score from mzcloud was kept.  
Finally, the CRPM dataset contained three MRI 
measurements, six proteins and two metabolites. 
Using these, the consensus CRPM RRMS vs. SPMS 
was compressed using PCA, now including all 
patients (except the transitioning patients), resulting 
in a large and highly significant (p=8.5×10-9) 
separation over the first principal component (Figure 
4A). Examining the variable loadings for the first 
principal component revealed that the size of the third 
ventricle, followed by galectin-9, contributed the most 
to the separation (Figure 4B). To investigate if the 
findings were therapy dependent, the PCA analysis 
was also performed excluding all patients on 
treatments (Figure S1), demonstrating an equally 
significant separation (p=8.1×10-9), indicating that the 
findings are not explained by treatments. 
In order to compare the integrated information 
to the separate variables alone, the separate variables 
were evaluated as the compressed information in the 
first principal component. Statistically significant 
differences were found between RRMS and SPMS for 
the size of the third ventricle: p=4.1×10-4, galectin-9: 
p=0.007, total T1: p=0.008, 20β-DHF: p=0.002, MCP-1: 
 
Figure 4. (A) Principal component analysis (PCA) of the eleven variables extracted by the variable selection procedure and the distribution of the first principal component 
(PC1) to the right displaying a highly significant difference (p=8.5×10-9). (B) The absolute values of the PCA loadings for PC1, showing the variable contribution in PC1. The 
variables have been color-coded by the class with the highest levels. (C) The eleven separate variables, where statistically significant differences were found between RRMS vs. 
SPMS for the size of the third ventricle, galectin-9, total T1, 20β-DHF, MCP-1, the size of the spinal cord, indolepyruvate, TGF-α, sCD40L and PDGF-AA. *, p<0.05; **, p<0.01; 
and ***, p<0.001. NS: non-significant; PC1: principal component one; PC2: principal component two; RRMS: relapsing-remitting multiple sclerosis; SPMS: secondary progressive 
multiple sclerosis. 
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p=0.006, the size of the spinal cord: p=3.2×10-5, 
indolepyruvate: p=0.002, TGF-α: p=0.01, sCD40L: 
p=0.007 and PDGF-AA: p=0.01, whereas TNF-α 
displayed a p=0.08 (Figure 4C).  
In addition, the ROC with its corresponding 
AUROC value for the combined information in the 
first principal component was compared to the ROCs 
and AUROC values of the separate variables. An 
increase from 0.85 for the best performing variables 
(the size of the spinal cord and third ventricle) to 0.97 
for the combined and compressed information was 
achieved (Figure 5), indicating that the combined 
information provided a higher performance. 
MBP, MDC, 20β-DHF and 5,6-DH-PGF1 
associate to a worse disease progression in 
SPMS patients 
To identify CRP variables and metabolites that 
associate with the disease progression of SPMS 
patients, the levels of all CRP variables, including the 
metabolites in the reduced metabolomics dataset, 
were investigated using Kruskal-Wallis tests based on 
the three groups of varying degree of clinical change. 
The proteins myelin basic protein (MBP) (p=0.04) and 
macrophage-derived chemokine (MDC) (p=0.05) as 
well as the metabolites 20β-DHF (p=0.02) and 
5,6-DH-PGF1 (p=0.05) achieved statistically significant 
differences between the groups (Figure 6). 
Interestingly, some of the transitioning patients 
(marked on the y-axis in Figure 6) displayed extreme 
levels of these proteins. Likewise, the combined 
information in the first principal component from the 
SPMS patients was investigated. No statistically 
significant difference (p=0.1) was found.  
Discussion 
We have shown that a model-based approach 
integrating clinical data, radiological, protein and 
metabolite measurements could be used for early 
diagnosis of SPMS patients. Using a linear 
combination of only eleven variables, the 
identification of SPMS patients could be improved. 
We also identified four biomarkers that were 
associated with a worse prognosis in patients with 
SPMS that could potentially be used to evaluate the 
disease course of these patients. 
 
 
Figure 5. Discriminative performance of the combined and single measurements. The receiver operating characteristic (ROC) curves for the compressed (CRPM) 
information in the first principal component (top left in red) as well as for the separate variables alone (black), with corresponding areas under the curve (AUROC). 
 
Figure 6. CRP and metabolites vs. the clinical degree of change. The proteins MBP and MDC and the metabolites 20β-DHF and 5,6-DH-PGF1 showed statistically 
significant differences between the groups, where 1 corresponds to no clinical change, 2 to an intermediate clinical change and 3 to a severe clinical change. The levels for the 
transitioning patients have been marked on the y-axis in blue arrows. 
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Multivariate diagnostics 
Technological advances have enabled us to 
measure multiple layers of biological information. 
However, integrating the information into MAAAs to 
be used in clinical care is still very rare. In health care, 
measurements are traditionally evaluated indepen-
dently, ignoring any combinatorial effect provided by 
combinations of measurements. By taking advantage 
of multiple variables, logistic regression-based models 
have proven to be superior for screening in prostate 
cancer [3], and the result of regression of clinical data 
can assist in identifying patients thought to be at high 
risk of cardiovascular disease [29]. 
In support of our variable selection, most of the 
extracted variables have been previously associated 
with SPMS and/or have been linked to the 
neurodegenerative stages of MS, e.g., decrease in the 
size of the spinal cord [30,31], increase in the size of 
the third ventricle [32], and accumulation of the 
number of T1 lesions in the later stages of SPMS [33]. 
Others have demonstrated increased levels of 
galectin-9 in active MS lesions [34], and we previously 
demonstrated that galectin-9 was significantly 
elevated in SPMS patients in comparison to RRMS 
patients and healthy controls [14]. Here, we 
demonstrated that galectin-9 is the most valuable 
protein measurement for distinguishing SPMS 
patients and the second most important variable in 
the CRPM dataset. We and others have previously 
shown that MCP-1 (also termed CCL2) is elevated in 
SPMS patients compared to RRMS patients and that 
TNF-α is elevated in RRMS and SPMS patients 
compared to controls [15,35]. We have previously 
shown that sCD40L identifies RRMS patients with the 
presence of Gd lesions, whereas PDGF-AA decrease 
in SPMS patients compared to RRMS and controls 
[15]. Finally, the pro-inflammatory cytokine TGF-α 
has been shown to be associated to CNS lesions in MS 
[36]. However, none of these performed as well as the 
combined and compressed information for 
distinguishing RRMS and SPMS patients. 
By defining three groups of varied clinical 
degree of impairment, we could demonstrate that 
MBP and MDC were elevated in SPMS patients with 
greater development of disability. MBP has been 
suggested as a potential marker for relapses in MS, as 
it is released during myelin sheath degradation 
[37,38], whereas MDC (also termed CCL22) is 
believed to play a role in various pathologies 
including the MS pathology and has been seen to be 
elevated in RRMS patients, in particular RRMS 
patients with Gd lesions, compared to controls [15] 
and to increase with disease progression in mice 
models with experimental autoimmune encephalo-
myelitis (EAE) [39]. CSF MDC has been found to be 
increased in female MS patients compared to male 
patients and female controls [40]. To investigate any 
potential gender effects on the MDC levels, Welch’s 
t-tests were done between all female and male 
patients, between female patients and controls and 
between female and male SPMS patients. We found 
no statistically significant difference between female 
and male patients (p=0.09), but a statistically 
significant increase was found in female patients 
compared to female controls (p=0.02). Amongst the 
SPMS patients, there was no statistically significant 
difference between female (n=10) and male (n=6) 
patients (p=0.8), indicating that the increase seen in 
the group of SPMS patients with the most severe 
disease progression is not due to gender. To our 
knowledge, the expression of MBP and MDC has not 
previously been demonstrated to associate with 
disease progression in SPMS patients. 
A few metabolomics studies on CSF from MS 
patients have previously been performed, e.g., 
suggesting alterations in energy and phospholipid 
metabolism compared to non-MS [8,9], and MS 
plasma has shown dysregulation of the methionine 
metabolism, related to mitochondrial abnormalities 
[10]. Alterations in phospholipid metabolism have 
also been found in serum of SPMS patients with 
respect to RRMS patients [41]. The most discriminant 
metabolites found herein represent novel findings in 
MS to a large extent; 5,6-DH-PGF1 is a prostaglandin. 
Prostaglandin F2α has previously been shown to 
decrease in plasma and increase in CSF of progressive 
MS patients compared to other neurological diseases 
[42,43], suggesting that prostaglandins may be 
involved in the pathology of MS. Furthermore, 
indolepyruvate is involved in tryptophan 
metabolism, where it catalyzes the nonoxidative 
decarboxylation of 3-indolepyruvate to 
3-indoleacetaldehyde. Indolepyruvate has also been 
found to act as a direct precursor for kynurenic acid in 
the presence of free radicals [44]. The kynurenine 
pathway is the major pathway in the tryptophan 
metabolism and has been recognized as central to the 
mechanisms of neurodegeneration [45]. The 
kynurenine pathway serum signature has also been 
shown to discriminate MS subtypes with an accuracy 
of 83% [46]. We found increased levels of 
indolepyruvate in SPMS patients compared to RRMS 
and controls that exhibited similar levels. 
In additional support of our findings, both 
20β-DHF and 5,6-DH-PGF1 were significantly 
increased in SPMS patients with greater development 
of disability, reinforcing their importance in the 
disease course of MS. Little is known about the 
glucocorticoid 20β-DHF, which is an abundant 
metabolite of cortisol. Previously, 20β-DHF measured 
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in urine has been associated with Cushing’s disease 
[47] and hypertension when measured in plasma [48]. 
Cortisol, however, has been reported to increase in the 
plasma and urine of MS patients [49–51]. Herein, we 
also find a statistically significant increase of CSF 
cortisol levels in SPMS patients compared to RRMS 
patients (Figure S2). However, we found the relative 
importance of SPMS diagnosis to be much higher for 
20β-DHF than that of cortisol. 
Assessment of early diagnosis of SPMS 
patients 
In the study cohort, the clinical follow-up of 
patients showed that four patients had transitioned 
from RRMS to SPMS within two to three years. As 
SPMS currently is diagnosed retrospectively, when 
the neurodegeneration potentially has been present 
for years, there is a possibility that these patients 
already had a neurodegenerative phenotype at the 
start of the study. Therefore, these patients were kept 
out of the variable selection procedure and instead 
assessed for early detection of SPMS. In the first 
principal component of the CRPM variables, three 
transitioning patients and one RRMS patient were 
closer to the SPMS patients than the RRMS patients 
(one with a score above the 95% confidence interval of 
the average SPMS score; (CI: 1.15, 2.39), p=2.1×10-5), 
indicating that these patients were at high risk for 
development of SPMS. As for the remaining 
transitioning patient who displayed values closer to 
the RRMS patients, the patient had either not 
developed a neurodegenerative profile or the 
neurodegeneration was too mild to be detected by the 
measurements included in the current study. 
Methodological aspects and limitations of the 
study  
Our goal was to combine information of 
carefully chosen variables for early identification of 
SPMS patients. The methodological strategy 
employed herein is novel to our knowledge, but the 
concept of information integration as MAAAs has 
been under discussion and employed for some time 
[3,52,53]. 
Three MRI, six protein and two metabolite 
measurements constructed the final CRPM dataset. 
When these were compressed down to a linear 
combination using PCA, the first principal component 
showed an increase in AUROC from 0.85, which was 
yielded by the best-performing single measurements, 
to 0.97. To estimate the value of adding the two 
metabolites 20β-DHF and indolepyruvate, the 
predictive accuracy of the compressed information of 
the final CRP variables was calculated 
(AUROC=0.93), indicating a modest increase in 
accuracy when adding the two metabolites. 
Random forest based on protein ratios has 
previously proven valuable for MS diagnostics. Using 
a set of 22/21 protein ratios, Barbour et al. achieved 
AUROC values of 0.98/0.91 (ERs of 0.09/0.11) when 
distinguishing MS from non-MS and progressive MS 
(SPMS and primary progressive MS, PPMS) from 
RRMS, validated on an independent cohort [7]. 
Decision trees or random forest comes with the 
advantage of being easy to interpret, but a major 
drawback of random forest is the ignorance to 
combinatorial effects (on top of the risk of overfitting). 
Using a multivariate approach like PLS-DA, 
measurements will be combined in an optimal way to 
maximize the variance among the groups of interest. 
If for example variable X and Y perform poorly 
independently, but very good when combined, they 
will be discarded by random forest but will be picked 
up by PLS-DA. However, the prevalent drawback of 
PLS-DA is the risk of overfitting, which we accounted 
for by performing repeated CV. The objective of CV is 
to extract true global variation, while ignoring 
variation unique to the dataset alone. An independent 
validation cohort as utilized by Barbour et al. would of 
course be superior to this approach and of great value 
to confirm our findings [7]. To check for overfitting in 
the models used in the variable selection, the models 
were rebuilt using all patients and the R2 and Q2 were 
extracted, where R2 describes how well the data 
explain the groups and Q2 is analogous to R2 except 
for being based on CV. The CRP (n=46) RRMS vs. 
SPMS model resulted in R2=0.70, p<0.05 and Q2=0.35, 
p<0.05 and the metabolomics RRMS vs. SPMS model 
utilizing all metabolites (n=606) demonstrated values 
of R2=0.87, p<0.05 and Q2=0.64, p<0.05, indicating that 
the metabolomics model demonstrates higher 
retention of predictivity, i.e., less overfitting (R2-Q2), 
and a higher overall predictivity (Q2 value). Similarly, 
but with lower values due to the inability to 
distinguish RRMS from controls, the Global models 
achieved values of R2=0.40, p<0.05 and Q2=0.16, 
p<0.05 (CRP) and R2=0.48, p<0.2 and Q2=0.28, p<0.05 
(metabolomics). Essentially this indicates that the 
metabolomics and the CRP models that we use to 
extract the CRPM variables contain information that 
should be important in the global MS population.  
To illustrate the final variables chosen by the 
variable selection included in CRPM, an unsupervised 
multivariate method was used (PCA). PCA works in a 
similar manner as PLS-DA, by decomposing the data 
into linear combinations of the variables. However, 
instead of maximizing the variation between 
predefined groups of interest, it maximizes present 
variation in the data not including any prior 
knowledge of grouping. PCA stores the most 
dominant variation in the first principal component 
 Theranostics 2018, Vol. 8, Issue 16 
 
 
http://www.thno.org 
4488 
and decreasing amounts of variation in the 
subsequent components, meaning the first principal 
component contains the most information. The first 
principal component of the combined CRPM 
variables showed a highly significant separation 
between the RRMS and SPMS patients (p=8.5×10-9), 
superior to the best performing separate variable 
(p=3.2×10-5). 
The most prominent limitation of the study is the 
limited number of patients and controls. While this 
increases the risk that our data do not accurately 
reflect the population, single-center studies have the 
advantage of avoiding inter-center variabilities and 
other confounders that can be difficult to correct for or 
handle [24]. Additionally, there were only four 
patients who transitioned from RRMS to SPMS during 
the follow-up period, limiting our findings for early 
detection. The fact that Barbour et al. attained a 
different set of protein markers (then evaluated as 
protein ratios) than extracted herein indicates that 
there are more proteins of interest for use in MS 
diagnostics [7]. Finally, as half of the RRMS patients 
(n=15) and one of the SPMS patients were on ongoing 
treatments, these treatments could potentially affect 
the top candidate variables. To assure that this was 
not the case, a PCA was performed on the CRPM 
variables, excluding all patients on ongoing 
treatments (Figure S1). The results showed that the 
separation between the RRMS and SPMS patients 
remained highly statistically significant over the first 
principal component (p=8.1×10-9). 
Future perspectives 
Integrative approaches hold great potential in 
future diagnostic assessments of many diseases, and 
as a general concept (MAAA) they could be applied to 
any medical condition with quantitative 
measurements. The challenges faced when translating 
this into routine health care would be the validation of 
a combinatorial scoring system, as the combined 
information as well as the single measurements 
included would need to be characterized.  
We also identified proteins and metabolites that 
were associated with development of disability. This 
may prove to be important in identifying patients at 
high risk for development of disability and thus 
highly suited for clinical trials of treatments for 
progressive MS. Furthermore, whether the levels of 
these proteins and metabolites can be influenced by 
therapeutic intervention will be an important area for 
future research. 
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